Skip to main content
SpringerLink
Log in

Rate versus rhythm control strategies for AF

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Optional statement

The safest long-term management strategy for elderly patients with persistent or recurrent episodes of atrial fibrillation (AF) is careful rate control with medications in conjunction with appropriate oral warfarin anticoagulation. Atrioventricular junctional ablation, with pacemaker implantation, may be necessary in patients who cannot have their rate controlled adequately, or have marked fluctuations in rate with standard medical therapies. Maintenance of sinus rhythm with repeat cardioversions, antiarrhythmic medications, device therapy, or atrial ablation approaches are appropriate to consider for younger patients and those elderly patients who suffer from substantial symptoms shown to be related directly to AF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kannel WB, Abbott RD, Savage DD, McNamara PM: Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982, 306:1018–1022.

    Article  PubMed  CAS  Google Scholar 

  2. Go AS, Hylek EM, Phillips KA, et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370–2375.

    Article  PubMed  CAS  Google Scholar 

  3. Benjamin EJ, Wolf PA, D’Agostino RB, et al.: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98:946–952.

    PubMed  CAS  Google Scholar 

  4. Nerheim P, Birger-Botkin S, Piracha L, Olshansky B: Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004, 110:247–252. Discusses the problem of persistent tachycardia and its effects causing a persistent cardiomyopathy, which may appear to be reversible but is not completely reversible.

    Article  PubMed  Google Scholar 

  5. Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN: Effect of radiofrequency catheter ablation on healthrelated quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation 1996, 94:1585–1591.

    PubMed  CAS  Google Scholar 

  6. Fuster V, Ryden LE, Asinger RW, et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001, 22:1852–1923. These guidelines are an important reference for an approach to the care of patients with AF.

    Article  PubMed  CAS  Google Scholar 

  7. Levy S, Maarek M, Coumel P, et al.: Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999, 99:3028–3035.

    PubMed  CAS  Google Scholar 

  8. Abusaada K, Sharma SB, Jaladi R, Ezekowitz MD: Epidemiology and management of new-onset atrial fibrillation. Am J Manag Care 2004, 10:S50-S57.

    PubMed  Google Scholar 

  9. Olshansky B: Management of atrial fibrillation after coronary artery bypass graft. Am J Cardiol 1996, 78:27–34.

    Article  PubMed  CAS  Google Scholar 

  10. Eagle KA, Guyton RA, Davidoff R, et al.: ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 2004, 44:1146–1154; e213-e310.

    Article  Google Scholar 

  11. Eaker ED, Sullivan LM, Kelly-Hayes M, et al.: Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study. Circulation 2004, 109:1267–1271.

    Article  PubMed  Google Scholar 

  12. Bourassa MG: Angiotensin II inhibition and prevention of atrial fibrillation and stroke. J Am Coll Cardiol 2005, 45:720–721.

    Article  PubMed  CAS  Google Scholar 

  13. Wachtell K, Lehto M, Gerdts E, et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005, 45:712–719.

    Article  PubMed  CAS  Google Scholar 

  14. Van Noord T, Crijns HJ, van den Berg MP, et al.: Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation. BMC Cardiovasc Disord 2005, 5:3,

    Article  PubMed  CAS  Google Scholar 

  15. Tsai CT, Lai LP, Lin JL, et al.: Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004, 109:1640–1646.

    Article  PubMed  CAS  Google Scholar 

  16. Tse HF, Lam YM, Lau CP, et al.: Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol 2001, 28:446–450.

    Article  PubMed  CAS  Google Scholar 

  17. Scardi S, Humar F, Pandullo C, Poletti A: Oral clonidine for heart rate control in chronic atrial fibrillation. Lancet 1993, 341:1211–1212.

    Article  PubMed  CAS  Google Scholar 

  18. Farshi R, Kistner D, Sarma JS, et al.: Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover openlabel study of five drug regimens. J Am Coll Cardiol 1999, 33:304–310.

    Article  PubMed  CAS  Google Scholar 

  19. Wyse DG, Waldo AL, DiMarco JP, et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825–1833. This is the largest and most important study addressing the issue of rate versus rhythm control in AF. The AFFIRM showed no advantage of attempting to maintain sinus rhythm. Rate control is as effective, if not safer, than trying to maintain sinus rhythm with an antiarrhythmic drug. If there is one manuscript that should be read on this topic, it is this one.

    Article  PubMed  CAS  Google Scholar 

  20. Olshansky B, Rosenfeld LE, Warner AL, et al.: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004, 43:1201–1208. The substudy of the AFFIRM trial evaluated the use of standard accepted drugs to control the rate in AF. It is the largest evaluation of such drugs in patients with AF. It appears that digoxin can control rate and that a β blocker is the most commonly used and effective approach in these patients.

    Article  PubMed  Google Scholar 

  21. Van Gelder IC, Hagens VE, Bosker HA, et al.: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834–1840. The RACE trial is one of the most important trials comparing rate and rhythm control in persistent AF. This and the AFFIRM trial are the leading articles in the field and should be read carefully. Both confirm no advantage of attempting to maintain sinus rhythm with an antiarrhythmic drug.

    Article  PubMed  Google Scholar 

  22. Kay GN, Bubien RS, Epstein AE, Plumb VJ: Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol 1988, 62:741–744.

    Article  PubMed  CAS  Google Scholar 

  23. Fitzpatrick AP, Kourouyan HD, Siu A, et al.: Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996, 131:499–507.

    Article  PubMed  CAS  Google Scholar 

  24. Brignole M, Gianfranchi L, Menozzi C, et al.: Prospective, randomized study of atrioventricular ablation and mode-switching, dual chamber pacemaker implantation versus medical therapy in drug-resistant paroxysmal atrial fibrillation. The PAF study. Paroxysmal Atrial Fibrillation. Europace 1999, 1:15–19.

    Article  PubMed  CAS  Google Scholar 

  25. Brignole M: Rhythm versus rate control after ablation and pacing for paroxysmal atrial fibrillation: clinical implications of the PAF 2 trial. Card Electrophysiol Rev 2003, 7:127–129.

    Article  PubMed  Google Scholar 

  26. Weerasooriya R, Davis M, Powell A, et al.: The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003, 41:1697–1702.

    Article  PubMed  Google Scholar 

  27. Geelen P, Brugada J, Andries E, Brugada P: Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol 1997, 20:343–348.

    Article  PubMed  CAS  Google Scholar 

  28. Clark DM, Plumb VJ, Epstein AE, Kay GN: Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997, 30:1039–1045.

    Article  PubMed  CAS  Google Scholar 

  29. Daoud EG, Weiss R, Bahu M, et al.: Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 1996, 78:1433–1436.

    Article  PubMed  CAS  Google Scholar 

  30. Dorian P, Mangat I: Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation. Card Electrophysiol Rev 2003, 7:276–279.

    Article  PubMed  Google Scholar 

  31. Botkin SB, Dhanekula LS, Olshansky B: Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs. Am Heart J 2003, 145:233–238. This is a large study of patients undergoing outpatient cardioversion. It shows that outpatient cardioversion is safe as long as the patients are anticoagulated before and after cardioversion with an International Normalized Ratio value greater than 2.0.

    Article  PubMed  Google Scholar 

  32. De Simone A, De Pasquale M, De Matteis C, et al.: Verapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). Eur Heart J 2003, 24:1425–1429.

    Article  PubMed  CAS  Google Scholar 

  33. Kuhlkamp V, Schirdewan A, Stangl K, et al.: Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000, 36:139–146.

    Article  PubMed  CAS  Google Scholar 

  34. Madrid AH, Marin IM, Cervantes CE, et al.: Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004, 5:114–120.

    Article  PubMed  CAS  Google Scholar 

  35. Naccarelli GV, Wolbrette DL, Khan M, et al.: Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003, 91:15D-26D.

    Article  PubMed  CAS  Google Scholar 

  36. Volgman AS, Carberry PA, Stambler B, et al.: Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998, 31:1414–1419.

    Article  PubMed  CAS  Google Scholar 

  37. Alboni P, Botto GL, Baldi N, et al.: Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-thepocket” approach. N Engl J Med 2004, 351:2384–2391.

    Article  PubMed  CAS  Google Scholar 

  38. Konety SH, Olshansky B: The “pill-in-the-pocket” approach to atrial fibrillation. N Engl J Med 2005, 352:1150–1151; author reply 1150–1151.

    Article  PubMed  CAS  Google Scholar 

  39. Zimetbaum P, Ho KK, Olshansky B, et al.: Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. Am J Cardiol 2003, 91:81–83.

    Article  PubMed  Google Scholar 

  40. Benditt DG, Williams JH, Jin J, et al.: Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1999, 84:270–277.

    Article  PubMed  CAS  Google Scholar 

  41. Guanzon AV, Crouch MA: Phase IV trial evaluating the effectiveness and safety of dofetilide. Ann Pharmacother 2004, 38:1142–1147.

    Article  PubMed  CAS  Google Scholar 

  42. Pedersen OD, Bagger H, Keller N, et al.: Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001, 104:292–296.

    PubMed  CAS  Google Scholar 

  43. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999, 341:857–865.

    Article  PubMed  CAS  Google Scholar 

  44. Zimmer J, Pezzullo J, Choucair W, et al.: Meta-analysis of antiarrhythmic therapy in the prevention of postoperative atrial fibrillation and the effect on hospital length of stay, costs, cerebrovascular accidents, and mortality in patients undergoing cardiac surgery. Am J Cardiol 2003, 91:1137–1140.

    Article  PubMed  Google Scholar 

  45. Roy D, Talajic M, Dorian P, et al.: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000, 342:913–920.

    Article  PubMed  CAS  Google Scholar 

  46. AFFIRM First Antiarrhythmic Drug Substudy Investigators: Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003, 42:20–29.

    Article  Google Scholar 

  47. Coplen SE, Antman EM, Berlin JA, et al.: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990, 82:1106–1116.

    PubMed  CAS  Google Scholar 

  48. Pappone C, Oreto G, Lamberti F, et al.: Catheter ablation of paroxysmal atrial fibrillation using a 3D mapping system. Circulation 1999, 100:1203–1208.

    PubMed  CAS  Google Scholar 

  49. Jais P, Sanders P, Hsu LF, et al.: Catheter ablation for atrial fibrillation. Heart 2005, 91:7–9.

    Article  PubMed  CAS  Google Scholar 

  50. Chandrasekhar R, Vasamreddy CR, Darshan D, et al.: Symptomatic and asymptomatic atrial fibrillation in patients undergoing radiofrequency catheter ablation [abstract]. J Am Coll Cardiol 2005, 45:1208.

    Google Scholar 

  51. Pappone C, Santinelli V, Manguso F, et al.: Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 2004, 109:327–334.

    Article  PubMed  Google Scholar 

  52. Hsu LF, Jais P, Sanders P, et al.: Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004, 351:2373–2383.

    Article  PubMed  CAS  Google Scholar 

  53. Pappone C, Rosanio S, Augello G, et al.: Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003, 42:185–197.

    Article  PubMed  Google Scholar 

  54. Handa N, Schaff HV, Morris JJ, et al.: Outcome of valve repair and the Cox maze procedure for mitral regurgitation and associated atrial fibrillation. J Thorac Cardiovasc Surg 1999, 118:628–635.

    Article  PubMed  CAS  Google Scholar 

  55. Hohnloser SH, Kuck KH, Lilienthal J: Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000, 356:1789–1794.

    Article  PubMed  CAS  Google Scholar 

  56. Carlsson J, Miketic S, Windeler J, et al.: Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003, 41:1690–1696.

    Article  PubMed  Google Scholar 

  57. Jenkins LS, Brodsky M, Schron E, et al.: Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005, 149:112–120.

    Article  PubMed  Google Scholar 

  58. Steinberg JS, Sadaniantz A, Kron J, et al.: Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004, 109:1973–1980.

    Article  PubMed  Google Scholar 

  59. Olshansky B, Sami M, Rubin A, et al.: Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. Am J Cardiol 2005, 95:404–405.

    Article  PubMed  CAS  Google Scholar 

  60. Corley SD, Epstein AE, DiMarco JP, et al.: Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004, 109:1509–1513.

    Article  PubMed  Google Scholar 

  61. Opolski G, Torbicki A, Kosior DA, et al.: Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004, 126:476–486.

    Article  PubMed  Google Scholar 

  62. Singh SN, Singh BN, Reda DJ, et al.: Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). Am J Cardiol 2003, 92:468–472.

    Article  PubMed  CAS  Google Scholar 

  63. Roy D: Rationale for the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Card Electrophysiol Rev 2003, 7:208–210.

    Article  PubMed  Google Scholar 

  64. de Denus S, Sanoski CA, Carlsson J, et al.: Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005, 165:258–262.

    Article  PubMed  Google Scholar 

  65. Olshansky B, Heller EN, Mitchell LB, et al.: Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. J Am Coll Cardiol 2005, 45:2026–2033.

    Article  PubMed  Google Scholar 

  66. Van Gelder IC, Crijns HJ, Tieleman RG, et al.: Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996, 156:2585–2592.

    Article  PubMed  Google Scholar 

  67. Zimetbaum P, Josephson ME: Is there a role for maintaining sinus rhythm in patients with atrial fibrillation? Ann Intern Med 2004, 141:720–726.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, University of Iowa Hospitals, 200 Hawkins Drive, 52242, Iowa City, IA, USA

    Brian Olshansky MD

Authors
  1. Brian Olshansky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olshansky, B. Rate versus rhythm control strategies for AF. Curr Treat Options Cardio Med 7, 371–381 (2005). https://doi.org/10.1007/s11936-005-0021-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-005-0021-3

Keywords

Search

Navigation